{"id":"fluticasone-propionate-fp","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Nervousness"},{"rate":null,"effect":"Throat irritation"},{"rate":null,"effect":"Oral candidiasis"}]},"_chembl":{"chemblId":"CHEMBL1473","moleculeType":"Small molecule","molecularWeight":"500.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a potent inhaled corticosteroid, fluticasone propionate exerts its anti-inflammatory effects by binding to intracellular glucocorticoid receptors and modulating the expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. This reduces mucus production, airway edema, and eosinophil infiltration. The drug is designed for topical delivery to the lungs to minimize systemic exposure while maximizing local therapeutic benefit.","oneSentence":"Fluticasone propionate is a corticosteroid that binds to glucocorticoid receptors in the cytoplasm, translocates to the nucleus, and suppresses inflammatory gene transcription to reduce airway inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:38.352Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Allergic rhinitis"}]},"trialDetails":[{"nctId":"NCT05608681","phase":"PHASE1, PHASE2","title":"A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).","status":"RECRUITING","sponsor":"Eupraxia Pharmaceuticals Inc.","startDate":"2023-03-31","conditions":"Eosinophilic Esophagitis","enrollment":117},{"nctId":"NCT06664619","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma","status":"RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2024-12-12","conditions":"Asthma","enrollment":724},{"nctId":"NCT06290102","phase":"PHASE1","title":"Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2024-05-16","conditions":"Asthma","enrollment":30},{"nctId":"NCT04527016","phase":"PHASE4","title":"Airway Microbiota Based Treatment of Asthma in Preschool Children","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2021-10-18","conditions":"Asthma in Children","enrollment":120},{"nctId":"NCT00394355","phase":"PHASE4","title":"Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Asthma","enrollment":566},{"nctId":"NCT00995475","phase":"PHASE4","title":"A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-10","conditions":"COPD","enrollment":18},{"nctId":"NCT04171167","phase":"NA","title":"The Causal Relation of Nasal Nitric Oxide Levels to the Severity of Chronic Rhinosinusitis and Its Inflammatory Phenotype","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tampere University Hospital","startDate":"2017-04-04","conditions":"Chronic Rhinosinusitis (Diagnosis)","enrollment":88},{"nctId":"NCT02215122","phase":"PHASE1","title":"Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2013-10","conditions":"Asthma, COPD","enrollment":40},{"nctId":"NCT02474017","phase":"PHASE1","title":"An Open Study to Assess the Robustness of the CRC749 Inhaler","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2015-05","conditions":"Asthma, COPD","enrollment":111},{"nctId":"NCT00783224","phase":"PHASE3","title":"A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09","conditions":"Perennial Allergic Rhinitis","enrollment":351},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT02437604","phase":"PHASE1","title":"Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-05","conditions":"Asthma","enrollment":43},{"nctId":"NCT02980133","phase":"PHASE3","title":"Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-12-28","conditions":"Asthma","enrollment":841},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT02680561","phase":"PHASE1","title":"A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-04","conditions":"Asthma","enrollment":20},{"nctId":"NCT02883439","phase":"NA","title":"Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate","status":"WITHDRAWN","sponsor":"University Hospital, Ghent","startDate":"2016-08","conditions":"Bioavailability Study","enrollment":""},{"nctId":"NCT02924688","phase":"PHASE3","title":"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-13","conditions":"Asthma","enrollment":2436},{"nctId":"NCT00692978","phase":"PHASE4","title":"Pharmacokinetics of Inhaled Monodisperse Fluticasone Propionate","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2008-08","conditions":"Healthy, Asthma","enrollment":30},{"nctId":"NCT02991859","phase":"PHASE2","title":"Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-02-09","conditions":"Asthma","enrollment":56},{"nctId":"NCT03207243","phase":"PHASE2","title":"Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Asthma","enrollment":165},{"nctId":"NCT01662778","phase":"PHASE4","title":"The Clinical Effect of Monodisperse Fluticasone Propionate in Asthma","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-12","conditions":"Asthma","enrollment":21},{"nctId":"NCT00903227","phase":"PHASE4","title":"Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-12","conditions":"Asthma, Allergic Rhinitis","enrollment":25},{"nctId":"NCT01388595","phase":"PHASE4","title":"Fluticasone and Salmeterol in Allergic Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-11","conditions":"Allergic Rhinitis","enrollment":23},{"nctId":"NCT03273946","phase":"","title":"Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-01-09","conditions":"Asthma","enrollment":158},{"nctId":"NCT01424397","phase":"PHASE2","title":"Intranasal SB-705498 in Allergic Rhinitis (AR) Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-14","conditions":"Rhinitis","enrollment":70},{"nctId":"NCT02730351","phase":"PHASE4","title":"Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05-25","conditions":"Asthma","enrollment":75},{"nctId":"NCT00830505","phase":"PHASE4","title":"Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2009-04","conditions":"Asthma","enrollment":38},{"nctId":"NCT00829257","phase":"PHASE4","title":"Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2009-01","conditions":"Asthma","enrollment":15},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""},{"nctId":"NCT00118716","phase":"PHASE4","title":"A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12-23","conditions":"Bronchospasm, Activity/Exercise Induced Bronchospasm","enrollment":248},{"nctId":"NCT02446418","phase":"PHASE3","title":"A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-09","conditions":"Asthma","enrollment":423},{"nctId":"NCT01915914","phase":"PHASE4","title":"A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-12-23","conditions":"Skin Diseases","enrollment":107},{"nctId":"NCT01342913","phase":"PHASE3","title":"A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":528},{"nctId":"NCT01462344","phase":"PHASE4","title":"6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Asthma","enrollment":6250},{"nctId":"NCT01475721","phase":"PHASE4","title":"SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-18","conditions":"Asthma","enrollment":11751},{"nctId":"NCT02301975","phase":"PHASE3","title":"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-03-01","conditions":"Asthma","enrollment":1526},{"nctId":"NCT01916226","phase":"PHASE4","title":"A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-08-01","conditions":"Rhinitis, Allergic, Perennial and Seasonal","enrollment":682},{"nctId":"NCT01540708","phase":"PHASE1","title":"A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-16","conditions":"Asthma","enrollment":36},{"nctId":"NCT01576718","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-04","conditions":"Asthma","enrollment":889},{"nctId":"NCT00398476","phase":"PHASE3","title":"Fluticasone Nasal Spray Patient Preference Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12-01","conditions":"Rhinitis, Allergic, Perennial","enrollment":127},{"nctId":"NCT00455923","phase":"PHASE4","title":"SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-05-03","conditions":"Asthma","enrollment":100},{"nctId":"NCT01817764","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":707},{"nctId":"NCT01879410","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-06-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":700},{"nctId":"NCT00370097","phase":"PHASE1","title":"FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-30","conditions":"Asthma","enrollment":16},{"nctId":"NCT01822899","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":717},{"nctId":"NCT01199757","phase":"","title":"A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07-10","conditions":"Rhinitis, Allergic, Perennial","enrollment":540},{"nctId":"NCT02113436","phase":"PHASE4","title":"Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-05-01","conditions":"Asthma","enrollment":300},{"nctId":"NCT01772368","phase":"PHASE2","title":"Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-01","conditions":"Asthma","enrollment":72},{"nctId":"NCT01479621","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-01","conditions":"Asthma","enrollment":909},{"nctId":"NCT02094937","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-27","conditions":"Asthma","enrollment":430},{"nctId":"NCT01156792","phase":"PHASE2","title":"Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Asthma","enrollment":162},{"nctId":"NCT00927758","phase":"PHASE2","title":"Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair","status":"COMPLETED","sponsor":"Sandoz","startDate":"2009-06","conditions":"Asthma","enrollment":105},{"nctId":"NCT01845025","phase":"PHASE4","title":"Study of Safety of Foradil in Patients With Persistent Asthma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-05","conditions":"Persistent Asthma","enrollment":827},{"nctId":"NCT00461500","phase":"PHASE4","title":"SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03","conditions":"Asthma","enrollment":81},{"nctId":"NCT00549146","phase":"PHASE3","title":"Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":290},{"nctId":"NCT00328718","phase":"PHASE3","title":"Pediatric ADVAIR DISKUS Versus Oral Montelukast Chewable Tablets","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10","conditions":"Asthma","enrollment":526},{"nctId":"NCT00517634","phase":"PHASE4","title":"Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08","conditions":"Asthma","enrollment":23},{"nctId":"NCT00296491","phase":"PHASE4","title":"Study Of Allergic Rhinitis In Patients Who Also Have Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09","conditions":"Asthma","enrollment":725},{"nctId":"NCT00452348","phase":"PHASE4","title":"A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Asthma","enrollment":628},{"nctId":"NCT00452699","phase":"PHASE4","title":"A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Asthma","enrollment":621},{"nctId":"NCT00163488","phase":"PHASE3","title":"Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-01","conditions":"Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever","enrollment":106},{"nctId":"NCT01248975","phase":"PHASE2","title":"Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12","conditions":"Asthma","enrollment":145},{"nctId":"NCT00920959","phase":"PHASE3","title":"Advair Pediatric Once-Daily","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-11","conditions":"Asthma","enrollment":908},{"nctId":"NCT01184118","phase":"NA","title":"DREAM: Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea Manifestations?","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2009-03","conditions":"Lung Disease","enrollment":36},{"nctId":"NCT00920543","phase":"PHASE4","title":"GSK BHR Study (Sont)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-02","conditions":"Asthma","enrollment":464},{"nctId":"NCT01324362","phase":"PHASE4","title":"GSK BHR Study (Sont - Second Study)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01","conditions":"Asthma","enrollment":446},{"nctId":"NCT01772056","phase":"PHASE3","title":"Efficacy Study of Topical Twice Weekly Fluticasone Treatment to Reduce Relapse in Atopic Dermatitis in Children","status":"TERMINATED","sponsor":"Elena Rubio Gomis","startDate":"2009-12","conditions":"Dermatitis, Atopic","enrollment":54},{"nctId":"NCT01516086","phase":"PHASE2","title":"A 12-Week Study in Adult Subjects With Asthma","status":"COMPLETED","sponsor":"Dey","startDate":"2012-03","conditions":"Asthma","enrollment":498},{"nctId":"NCT01516073","phase":"PHASE2","title":"12-Week Study in Adult Subjects With Asthma","status":"COMPLETED","sponsor":"Dey","startDate":"2012-03","conditions":"Asthma","enrollment":629},{"nctId":"NCT00116402","phase":"PHASE1","title":"A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2005-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":15},{"nctId":"NCT01287351","phase":"","title":"Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2004-01","conditions":"Asthma","enrollment":82903},{"nctId":"NCT01908075","phase":"","title":"Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2011-01","conditions":"Asthma","enrollment":194723},{"nctId":"NCT01877954","phase":"","title":"Qvar vs FP in Pediatrics","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2011-02","conditions":"Asthma","enrollment":2654},{"nctId":"NCT00774761","phase":"PHASE2","title":"A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Dey","startDate":"2008-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":97},{"nctId":"NCT00557440","phase":"PHASE2","title":"Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Asthma","enrollment":37},{"nctId":"NCT01141439","phase":"","title":"Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2001-01","conditions":"Asthma","enrollment":815377},{"nctId":"NCT01729351","phase":"","title":"Qvar Therapy in Smoking Asthmatics","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2011-11","conditions":"Asthma, Smoking","enrollment":7195},{"nctId":"NCT00480649","phase":"PHASE4","title":"Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-01","conditions":"Asthma","enrollment":424},{"nctId":"NCT01242098","phase":"","title":"Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2008-01","conditions":"Asthma","enrollment":137},{"nctId":"NCT01400568","phase":"NA","title":"Suitability of a Low Dose Lipopolysaccharide (LPS) Inhalation as a Challenge Model","status":"COMPLETED","sponsor":"Fraunhofer-Institute of Toxicology and Experimental Medicine","startDate":"2011-08","conditions":"Healthy","enrollment":12},{"nctId":"NCT00307970","phase":"PHASE4","title":"Impact of Anti-static Chamber/Mask","status":"COMPLETED","sponsor":"University of Florida","startDate":"2003-04","conditions":"Asthma","enrollment":12},{"nctId":"NCT00308932","phase":"PHASE4","title":"Effect of Age and Device on Delivery of Fluticasone","status":"COMPLETED","sponsor":"University of Florida","startDate":"2003-02","conditions":"Asthma","enrollment":60},{"nctId":"NCT01141452","phase":"","title":"Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2001-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":815377},{"nctId":"NCT01246921","phase":"PHASE4","title":"Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2009-09","conditions":"Patients With Active Non-segmental Vitiligo., Evaluation of the Efficacy of UVB and Fluticason Proprionate 0.05%, Cream Compared to NB-UVB Alone in Patients With Non-segmental Vitiligo","enrollment":50},{"nctId":"NCT01141465","phase":"","title":"Real-world Effectiveness of Combination Therapy in Asthma","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2001-01","conditions":"Asthma","enrollment":815377},{"nctId":"NCT00448435","phase":"PHASE3","title":"Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Bronchial Asthma","enrollment":51},{"nctId":"NCT00403286","phase":"PHASE2","title":"A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Dey","startDate":"2006-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":457}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"ABDOMINAL PAIN UPPER"},{"count":1,"reaction":"CONTUSION"},{"count":1,"reaction":"CUSHING^S SYNDROME"},{"count":1,"reaction":"DECREASED APPETITE"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"HIRSUTISM"},{"count":1,"reaction":"LIVEDO RETICULARIS"},{"count":1,"reaction":"MALAISE"},{"count":1,"reaction":"NAUSEA"}],"_approvalHistory":[],"publicationCount":782,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["No other names applicable"],"phase":"marketed","status":"active","brandName":"Fluticasone Propionate (FP)","genericName":"Fluticasone Propionate (FP)","companyName":"Dey","companyId":"dey","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluticasone propionate is a corticosteroid that binds to glucocorticoid receptors in the cytoplasm, translocates to the nucleus, and suppresses inflammatory gene transcription to reduce airway inflammation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD), Allergic rhinitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}